|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.10 / 0.19|
The company says it didn't make an acquisition offer for the biotech.
Somebody doesn't like Sara Lee, the next Jobs, and what Estee Lauder can't cover up.
For the second straight session, the industrials hit an all-time high. The Nasdaq rises more than 2%.
Both ImClone and Carl Icahn have valid points, but the battle's likely a lose-lose for all.
The company says Carl Icahn wouldn't support another firm's $36-a-share buyout offer.
Jailbound or not, Fastow, Ebbers, Alexander and Dunn deserve our understanding.
This biotech is haunted by competition and internal strife. Plus, more on the Dow's flirtation with history.
The billionaire investor plans to buy up to $500 million of the department-store-operator's stock.
Hedge funds lead us down the primrose path. Plus, what do Halliburton and McDonald's have to do with bad spinach?
ImClone in-fighting; BP bungling; addled Amaranth; Ford flummoxed; Dell hard sell.
Major changes are taking place at the biotech, including the addition of Carl Icahn to the board.
Yahoo!'s warning and weaker housing starts inject anxiety. Plus, liquidity abounds.
Sliding oil prices could give the market a lift, if bad housing news doesn't grab the spotlight.
Paris Hilton, Sony, Fox and the federal courts provide a terrifying vision of the not-so-distant future.
Also, three of his recommended candidates will be on the list of director nominees.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.